← Back to Search

Monoclonal Antibodies

Nemolizumab for Eczema

Phase 3
Waitlist Available
Research Sponsored by Galderma R&D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 16
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat atopic dermatitis.

Eligible Conditions
  • Eczema

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects with EASI-75
Proportion of subjects with an IGA success (IGA of 0 or 1) and a ≥ 2-point reduction
Secondary outcome measures
Proportion of subjects with EASI-75 and improvement of PP NRS ≥ 4
Proportion of subjects with IGA success and improvement of PP NRS ≥ 4
Proportion of subjects with PP NRS < 2
+2 more

Side effects data

From 2018 Phase 2 trial • 226 Patients • NCT03100344
33%
Nasopharyngitis
20%
Dermatitis atopic
13%
Headache
7%
Nausea
7%
Sinusitis
7%
Upper respiratory tract infection
5%
Diarrhoea
5%
Urinary tract infection
4%
Blood creatine phosphokinase increased
4%
Oral herpes
4%
Asthma
2%
Back pain
2%
Arthralgia
2%
Cardio-respiratory arrest
2%
Pyrexia
2%
Cough
2%
Abdominal pain
2%
Staphylococcal sepsis
2%
Asthenia
2%
Post-traumatic amnestic disorder
2%
Pneumonia aspiration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nemolizumab (10 mg)
Nemolizumab (90 mg)
Nemolizumab (30 mg)
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NemolizumabExperimental Treatment1 Intervention
Nemolizumab Active
Group II: PlaceboPlacebo Group1 Intervention
Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nemolizumab
2021
Completed Phase 3
~2750

Find a Location

Who is running the clinical trial?

Galderma R&DLead Sponsor
299 Previous Clinical Trials
59,479 Total Patients Enrolled
12 Trials studying Eczema
3,262 Patients Enrolled for Eczema

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA given the okay to market and sell Nemolizumab?

"Nemolizumab has been given a safety score of 3 by our researchers at Power. This is due to the fact that it is a Phase 3 trial, meaning there is both efficacy and safety data available."

Answered by AI

Has this kind of clinical trial been done before?

"There are a total of 10 ongoing clinical trials for the drug Nemolizumab in 237 cities and 25 countries as of right now. The first study was completed in 2019 by Galderma R&D. That initial trial included 750 patients and reached Phase 3 approval. 18291 studies have been completed since that time."

Answered by AI

In how many distinct geographical areas is this research being conducted?

"86 medical centres across Canada, including locations in Ottawa, Toronto and Waterloo are currently enrolling patients for this clinical trial. To minimize the inconvenience of travel, it is recommended that potential participants select a site nearest to them."

Answered by AI

Are patients able to sign up for this experiment at this time?

"No, this particular trial is no longer recruiting patients. The study was first made public on June 30th, 2019 and the most recent update was October 17th, 2022. For individuals who are looking for other studies, there are presently 257 trials actively searching for patients with moderate-to-severe atopic dermatitis and 10 studies for Nemolizumab that have open enrolment."

Answered by AI

Are there any other examples of Nemolizumab being used in a medical setting?

"Nemolizumab is being studied in 10 clinical trials, 7 of which are Phase 3. Most of the research for this medication is happening in Regensburg, but there are 1161 medical centres running trials across the globe."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
2019. "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03985943.
~164 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top